Latest news with #AlecStranahan
Business Insider
7 days ago
- Business
- Business Insider
Bank of America Securities Remains a Buy on Revolution Medicines (RVMD)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Revolution Medicines (RVMD – Research Report) on May 30 and set a price target of $78.00. Confident Investing Starts Here: Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Y-Mabs Therapeutics, and TG Therapeutics. According to TipRanks, Stranahan has an average return of -11.2% and a 35.35% success rate on recommended stocks. Currently, the analyst consensus on Revolution Medicines is a Strong Buy with an average price target of $70.63.
Yahoo
21-05-2025
- Business
- Yahoo
BofA Reiterates Hold Rating on Novavax (NVAX) Stock
On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of 2025. Stranahan cited that this will mitigate near-term risks. However, the analyst pointed out that the post-marketing commitments and the need for further trials are already considered in Novavax's guidance, indicating minimal influence on the stock's performance. A person holding a syringe filled with a vaccine, implying the companys impact on health and wellbeing. As the demand for COVID vaccines remains sizeable among older populations, the stricter labeling may not have a drastic impact on Nuvaxovid's potential market. Overall, the analyst maintains a neutral view on the stock, considering the full potential of Novavax's pipeline remains to be unlocked. Novavax, Inc. (NASDAQ:NVAX) is a biotechnology firm that is engaged in the discovery, development, and commercialization of vaccines to protect against serious diseases worldwide. While we acknowledge the potential of NVAX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVAX and that has 100x upside potential, check out our report about this cheapest AI stock. Read Next: and . Disclosure. None. Sign in to access your portfolio
Business Insider
15-05-2025
- Business
- Business Insider
Bank of America Securities Remains a Buy on Beam Therapeutics (BEAM)
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) yesterday and set a price target of $43.00. The company's shares closed yesterday at $17.24. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Stranahan is an analyst with an average return of -12.1% and a 34.60% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Candel Therapeutics, and Novavax. In addition to Bank of America Securities, Beam Therapeutics also received a Buy from JonesTrading's Soumit Roy in a report issued on May 8. However, on May 7, Barclays maintained a Hold rating on Beam Therapeutics (NASDAQ: BEAM).
Business Insider
15-05-2025
- Business
- Business Insider
Agios Pharma (AGIO) Gets a Buy from Bank of America Securities
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Agios Pharma (AGIO – Research Report) yesterday and set a price target of $52.00. The company's shares closed yesterday at $28.03. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Stranahan covers the Healthcare sector, focusing on stocks such as Beam Therapeutics, Candel Therapeutics, and Novavax. According to TipRanks, Stranahan has an average return of -12.1% and a 34.60% success rate on recommended stocks. In addition to Bank of America Securities, Agios Pharma also received a Buy from Cantor Fitzgerald's Eric Schmidt FCA in a report issued on May 13. However, on May 2, Leerink Partners maintained a Hold rating on Agios Pharma (NASDAQ: AGIO). Based on Agios Pharma's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.73 million and a GAAP net loss of $89.29 million. In comparison, last year the company earned a revenue of $8.19 million and had a GAAP net loss of $81.55 million
